Neurodegenerative diseases represent a significant area of unmet need and market opportunity for the pharmaceutical and biopharmaceutical industries. The neurodegenerative disease therapy market is poised to increase from 16 million patients today to an estimated 21 million patients in 2010 in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Outlook for Neurodegenerative Disease Therapy Markets is a new report published by Decision Resources, Inc., that examines long-term neurodegeneration that leads to such diseases as Alzheimer's disease, Parkinson's disease, miscellaneous movement disorders, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and diabetic neuropathy.
Alzheimer's disease remains the biggest challenge facing the drug industry in the neurodegenerative disease arena. Preliminary evidence, still to be corroborated by larger and longer clinical trials, shows that the effect of the cholinesterase inhibitors donepezil, rivastigmine, and galanthamine on cognition is not entirely symptomatic if treatment is extended to one year or more. Such drugs might be, to a degree, capable of indirectly modifying progression of neurodegeneration by providing continued artificial stimulation to the cholinergic system, which could in turn work against secretion of amyloidogenic precursors.
Other degenerative conditions of the CNS that will be discussed in this report-multiple sclerosis, Huntington's disease, and ALS-have a comparatively minor impact on health care resources, even though they are devastating for the affected individuals and those who care for them. An important exception is diabetic neuropathy, a major form of peripheral neurodegeneration, which can lead to excruciating pain and limb loss. Because the number of type 2 diabetics is constantly rising-especially among the young and middle-aged-and because diabetics cannot avoid neuropathy entirely if they live with diabetes for decades, the need for permanent outpatient care is greatly expanding for this patient group.
Research still has a long way to go until treatments of the underlying causes of chronic neurodegeneration can be developed. The spectrum of investigational agents is broader and more specific to each condition than are current therapies. This report therefore focuses on the feasibility of the various approaches that have reached the clinical stage. We also include recent patenting activity for each condition.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends.
Outlook for Neurodegenerative Disease Therapy Markets is available for $3,200.00. Contact: Cindy Ohlman, 781.296.2521 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org (e-mail). http://www.dresources.com
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Cindy Ohlman of Decision Resources, Inc., 781-296-2521,